Abstract: UDPS detected drug-resistance mutations that were not detected by PCR in 10 samples from 5 NRTI-treated patients, including the lamivudine-resistance mutation
V173L (in 5 samples), the entecavir-resistance mutations
T184S (in 2 samples) and
S202G (in 1 sample), the adefovir-resistance mutation
N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations
V173L,
L180M,
A181T, and
M204V (in 1 sample).